NANOVIRICIDES Files 8-K on Shareholder Vote Matters; Not Emerging Growth Co.
Ticker: NNVC · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1379006
| Field | Detail |
|---|---|
| Company | Nanoviricides, Inc. (NNVC) |
| Form Type | 8-K |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, regulatory-filing
TL;DR
**NANOVIRICIDES filed an 8-K about a shareholder vote, confirming it's a fully regulated company, not an emerging growth one.**
AI Summary
NANOVIRICIDES, INC. filed an 8-K on January 19, 2024, reporting an event on January 13, 2024, related to the submission of matters to a vote of security holders. This filing indicates that the company is not an emerging growth company and has not elected to use the extended transition period for new accounting standards. For investors, this means the company is subject to full SEC reporting requirements, which could impact administrative costs and transparency, potentially affecting stock valuation.
Why It Matters
This filing confirms NANOVIRICIDES, INC. operates under full public company regulations, which can influence investor perception of its maturity and compliance burden.
Risk Assessment
Risk Level: low — This filing is purely administrative, reporting a past event and confirming company status, posing minimal direct risk to investors.
Analyst Insight
A smart investor would note that NANOVIRICIDES, INC. is not an emerging growth company, meaning it adheres to standard SEC reporting and accounting requirements, which implies a higher level of regulatory scrutiny and potentially more transparent financial disclosures compared to smaller, less regulated entities.
Key Players & Entities
- NANOVIRICIDES, INC. (company) — the registrant filing the 8-K
- January 13, 2024 (date) — date of the earliest event reported
- January 19, 2024 (date) — date the 8-K was filed
- 001-36081 (other) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 13, 2024, and pertained to the 'Submission of Matters to a Vote of Security Holders'.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 19, 2024, as indicated by the 'FILED AS OF DATE: 20240119'.
Is NANOVIRICIDES, INC. considered an 'emerging growth company' according to this filing?
No, the filing explicitly states that NANOVIRICIDES, INC. is not an 'emerging growth company' by having the 'Emerging growth company' box unchecked and the 'If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period...' box also unchecked.
What is the business address of NANOVIRICIDES, INC. as listed in the filing?
The business address of NANOVIRICIDES, INC. is 1 Controls Drive, Shelton, Connecticut 06484.
What is the primary purpose of this 8-K filing, as indicated by the 'ITEM INFORMATION'?
The primary purpose of this 8-K filing, as indicated by the 'ITEM INFORMATION', is the 'Submission of Matters to a Vote of Security Holders'.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 14.6 · Accepted 2024-01-19 16:44:48
Filing Documents
- tm243719d1_8k.htm (8-K) — 33KB
- 0001104659-24-005254.txt ( ) — 201KB
- nnvc-20240113.xsd (EX-101.SCH) — 3KB
- nnvc-20240113_lab.xml (EX-101.LAB) — 33KB
- nnvc-20240113_pre.xml (EX-101.PRE) — 22KB
- tm243719d1_8k_htm.xml (XML) — 3KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On January 13, 2024, NanoViricides, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Meeting"). At the meeting, 4,874,236 shares of the Company's common stock and 507,615 shares of Series A Convertible Preferred Stock ("Series A Preferred Shares") entitled to vote at the Meeting, as of the record date of November 13, 2023, were present in person or by proxy, representing 48.2% of the Company's outstanding voting capital stock and constituting a quorum for the transaction of business. With a quorum present, the required shareholders approved the following proposals: (i) the re-election of Anil Diwan as a Class I Director for a two-year term expiring at the 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal; (ii) an advisory vote on the compensation of the Company's named executive officers; (iii) the approval of an award of 10,204 Series A Preferred Shares to Anil Diwan in connection with the extension of his employment as the Company's President; and (iv) the ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2024. Each proposal is described in more detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on December 4, 2023. The voting results of the shares of the Company's voting stock for each proposal are set forth below: Proposal 1 – Election of Director - Re-Election of Anil Diwan as a Class I Director: Votes For Votes Against Votes Abstained Broker Non-Votes 5,590,467 308,092 488,175 3,056,966 Proposal 2 – Advisory Vote on Compensation of Named Executive Officers: Votes For Votes Against Votes Abstained Broker Non-Votes 5,572,378 788,423 25,933 3,056,966 Proposal 3 – Approval of Convertible Preferred Stock Grant to Anil Diwan: Votes
SIGNATURES
SIGNATURES PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED. NANOVIRICIDES, INC. Date: January 19, 2024 By: /s/ Anil Diwan Name: Anil Diwan Title: Chairman, President